diflorasone has been researched along with Diabetes Mellitus, Type 2 in 1 studies
*Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, M; Izumi, K; Nishie, W; Oya, K; Shimizu, H; Taguchi, S | 1 |
1 other study(ies) available for diflorasone and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Bullous pemphigoid following the replacement of vildagliptin with anagliptin.
Topics: Administration, Cutaneous; Aged, 80 and over; Betamethasone; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Substitution; Glucocorticoids; Humans; Male; Pemphigoid, Bullous; Pyrimidines; Treatment Outcome; Vildagliptin | 2017 |